CYTOSINE-ARABINOSIDE AND CISPLATIN FOR ADVANCED BREAST-CANCER - A PHASE-II STUDY OF THE CANCER AND LEUKEMIA GROUP-B

被引：0
|
作者：
OSTER, MW
SCHILSKY, RL
FARAGGI, D
KORZUN, AH
PERRY, M
MOORE, A
KALRA, J
WOOD, WC
HENDERSON, IC
机构：
[1] LONG ISL JEWISH MED CTR,NEW HYDE PK,NY
[2] COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032
[3] CORNELL UNIV,MED CTR,COLL MED,NEW YORK,NY 10021
[4] UNIV CHICAGO,PRITZKER SCH MED,CHICAGO,IL 60637
[5] HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115
[6] HARVARD UNIV,SCH MED,BOSTON,MA 02115
[7] UNIV MISSOURI,MED CTR,SCH MED,COLUMBIA,MO 65201
来源：
CANCER | 1991年 / 68卷 / 08期
关键词：
D O I：
10.1002/1097-0142(19911015)68:8<1696::AID-CNCR2820680807>3.0.CO;2-B
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Forty-four women with advanced breast cancer participated in a prospective clinical trial to evaluate the efficacy and toxicity of a regimen consisting of cytosine arabinoside and cisplatin. All patients had previously received chemotherapy. Three patients (7%) responded to therapy with response durations of 153, 160, and 441 days. The median time to disease progression and median survival time in all 44 patients were 2.3 and 5 months, respectively. This regimen had significant toxicity, with most patients experiencing severe or life-threatening hematologic, renal, or infectious complications. This regimen cannot be recommended for previously treated patients with advanced breast cancer.
引用
收藏
页码：1696 / 1698
页数：3
相关论文
共 50 条
  • [21] MITOXANTRONE, A PHASE-II STUDY IN ADVANCED BREAST-CANCER
    COLEMAN, RE
    MAISEY, MN
    KNIGHT, RK
    RUBENS, RD
    BRITISH JOURNAL OF CANCER, 1984, 49 (03) : 390 - 390
  • [22] PHASE-II STUDY OF MAYTANSINE IN ADVANCED BREAST-CANCER
    EDMONSON, JH
    RUBIN, J
    KVOLS, LK
    OCONNELL, MJ
    FRYTAK, S
    GREEN, SJ
    CANCER TREATMENT REPORTS, 1981, 65 (5-6): : 536 - 537
  • [23] PHASE-II STUDY OF NAVELBINE IN ADVANCED BREAST-CANCER
    CANOBBIO, L
    BOCCARDO, F
    PASTORINO, G
    BREMA, F
    MARTINI, C
    RESASCO, M
    SANTI, L
    SEMINARS IN ONCOLOGY, 1989, 16 (02) : 33 - 36
  • [24] A PHASE-II STUDY OF MITOZANTRONE IN ADVANCED BREAST-CANCER
    THOMPSON, PI
    HARVEY, VJ
    BRITISH JOURNAL OF CANCER, 1988, 58 (02) : 268 - 268
  • [25] PHASE-II STUDY OF AMONAFIDE IN ADVANCED BREAST-CANCER
    SCHEITHAUER, W
    DITTRICH, C
    KORNEK, G
    HAIDER, K
    LINKESCH, W
    GISSLINGER, H
    DEPISCH, D
    BREAST CANCER RESEARCH AND TREATMENT, 1991, 20 (01) : 63 - 67
  • [26] PHASE-II STUDY OF TCNU IN ADVANCED BREAST-CANCER
    DOMBERNOWSKY, P
    CLAVEL, M
    SMYTH, JF
    HOWELL, A
    VANGLABEKKE, M
    RENARD, J
    PINEDO, HM
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (08): : 1377 - 1378
  • [27] PHASE-II STUDY OF ANGUIDINE IN ADVANCED BREAST-CANCER
    YAP, HY
    MURPHY, WK
    DISTEFANO, A
    BLUMENSCHEIN, GR
    BODEY, GP
    CANCER TREATMENT REPORTS, 1979, 63 (05): : 789 - 791
  • [28] IDARUBICIN IN ADVANCED BREAST-CANCER - A PHASE-II STUDY
    LIONETTO, R
    PRONZATO, P
    CONTE, PF
    SERTOLI, MR
    AMOROSO, D
    ROSSO, R
    CANCER TREATMENT REPORTS, 1986, 70 (12): : 1439 - 1440
  • [29] A PHASE-II STUDY OF MITOXANTRONE IN ADVANCED BREAST-CANCER
    PRONZATO, P
    ARDIZZONI, A
    CONTE, PF
    GULISANO, M
    LIONETTO, R
    REPETTO, L
    SCORNAVACCHE, V
    SERTOLI, MR
    ROSSO, R
    CHEMIOTERAPIA, 1986, 5 (03): : 150 - 153
  • [30] PHASE-II STUDY OF TENIPOSIDE IN ADVANCED BREAST-CANCER
    BOAS, J
    RASMUSSEN, D
    HANSEN, OP
    ENGELHOLM, SA
    DOMBERNOWSKY, P
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 25 (06) : 463 - 464
12345